Cargando…
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2. Beyond the regulation of glucose homeostasis...
Autores principales: | Feijóo-Bandín, Sandra, Aragón-Herrera, Alana, Otero-Santiago, Manuel, Anido-Varela, Laura, Moraña-Fernández, Sandra, Tarazón, Estefanía, Roselló-Lletí, Esther, Portolés, Manuel, Gualillo, Oreste, González-Juanatey, José Ramón, Lago, Francisca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144929/ https://www.ncbi.nlm.nih.gov/pubmed/35628443 http://dx.doi.org/10.3390/ijms23105634 |
Ejemplares similares
-
Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Adipokines and Inflammation: Focus on Cardiovascular Diseases
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2020) -
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers
por: Aragón-Herrera, Alana, et al.
Publicado: (2022) -
Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives
por: Feijóo-Bandín, Sandra, et al.
Publicado: (2017)